Small Pharma kicks off its Phase II study of DMT-and-psychotherapy treatment to treat depression

4:32
 
Share
 

Manage episode 302941602 series 2891889
By Proactive Investors. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Small Pharma Inc (TSX-V:DMT) chief medical and scientific officer Dr Carol Routledge tells Proactive it has completed phase one and started phase two of the clinical trial of its psychedelic-assisted therapy for major depressive disorder (MDD). The company’s DMT-based lead candidate, SPL026, is being tested in combination with psychotherapy. Dr Routledge says the intravenous drug was found to be very well tolerated in individuals with no previous experience of psychedelics.

1513 episodes